InsiderTrades

Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Accepted 2022-03-08 00:00:00 ET · period of report 2022-03-04 · accession 0001209191-22-017058 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2022-03-08 2022-03-04+ TEVA Schultz Kare Pres, CEO, Dir M - OptEx — +293.6K 1.43M +26% —
D 2022-03-08 2022-03-04 TEVA Schultz Kare Pres, CEO, Dir A - Grant $0.00 +402.1K 402.1K New $0
DM 2022-03-08 2022-03-04+ TEVA Schultz Kare Pres, CEO, Dir M - OptEx $0.00 -293.6K 213.9K -58% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Ordinary Shares 2022-03-04 M A 59,701 — 1,192,197 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
2 Common Ordinary Shares 2022-03-04 M A 162,593 — 1,354,790 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
3 Common Ordinary Shares 2022-03-05 M A 71,292 — 1,426,082 D — — (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
4 Derivative Restricted Share Units 2022-03-04 A A 402,144 $0.00 402,144 D — · — to — 402,144 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F5) Restricted share units were granted on March 4, 2022, with 100,536 vesting on each of March 4, 2023, March 4, 2024, March 4, 2025 and March 4, 2026.
5 Derivative Restricted Share Units 2022-03-04 M D 162,593 $0.00 0 D — · — to — 162,593 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F4) Restricted share units were received on February 8, 2022 upon satisfaction of performance criteria and vested on March 4, 2022.
6 Derivative Restricted Share Units 2022-03-04 M D 59,701 $0.00 59,702 D — · — to — 59,701 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F3) Restricted share units were granted on March 4, 2019, with 59,701 having vested on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023.
7 Derivative Restricted Share Units 2022-03-05 M D 71,292 $0.00 213,879 D — · — to — 71,292 Ordinary Shares (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F6) Restricted share units were granted on March 5, 2021, with 71,292 having vested on March 5, 2022, 71,292 vesting on each of March 5, 2023 and March 5, 2024, and 71,295 vesting on March 5, 2025.